The relationship between serum ammonia level and neurologic complications in patients with acute glufosinate ammonium poisoning: A prospective observational study

Abstract

Glufosinate ammonium poisoning can cause neurological complications even after a symptom-free period. We prospectively investigated the predictors of neurologic complications in acute glufosinate ammonium poisoning and the change of serum ammonia level as a predictor of patient’s presence and recovery of neurologic complication. This prospective observational study collected data from consecutive patients diagnosed with acute glufosinate ammonium poisoning between September 2014 and June 2016. Serum ammonia was serially measured. The patients were divided into two groups: the neurologic complication group and the nonneurologic complication group. We also defined 25 other insecticide- or herbicide-poisoned patients as controls. The neurologic complication group included 18 patients (72.0%). The latency period for neurologic complications was within 48-h postingestion. The peak ammonia level was statistically higher in the neurologic complication group than in the control group (p < 0.001) and the nonneurologic complication groups (p = 0.001). There was a statistical difference between the nonneurologic complication group and the neurologic complication group (p = 0.0085) in terms of ingested amount. The peak ammonia was the only predictor for the development of neurologic complications (the optimal cutoff: 90 μg/dL). In patients with mental changes, the mean serum ammonia levels before and after recovery of the mental changes were statistically different (p = 0.0019). In acute glufosinate ammonium poisoning, serial serum ammonia level measurements are needed and a serum peak ammonia level greater than 90 μg/dL is a predictor of neurologic complications. Also, it is important to treat the hyperammonemia in acute glufosinate ammonium poisoning.

Keywords

Herbicide poisonings neurotoxicity laboratory test

Introduction

Glufosinate, a phosphorus-containing amino acid, is an active ingredient in nonselective herbicides and is a glutamate analog that inhibits glutamine synthetase (GS) in plants and blocks glutamine synthesis from glutamate and ammonia. The associated intracellular accumulation of ammonia causes tissue necrosis and death.^1
–3 Glufosinate ammonium–containing herbicides are formulated with the ammonia salt of glufosinate, an anionic surfactant, such as sodium polyoxyethylene alkylether sulfate and propylene glycol as a solvent.^4,5

Glufosinate ammonium herbicide is now available in many countries, and its use has gradually increased.⁶ Since 2013, glufosinate ammonium herbicide has seen greater use as a nonselective herbicide in Korea because sales of Gramoxone® (paraquat) were banned in Korea in November 2012; glufosinate ammonium is advertised to have a low toxicity to both humans and the environment. However, previous reports indicate that glufosinate ammonium poisoning can cause severe complications, such as serious disturbances of consciousness, seizures, and amnesia, after latent periods of 4–60 h following ingestion.^{1,2,7

–11} Therefore, glufosinate-poisoned patients should be carefully observed for several days after ingestion, even if the clinical signs are not remarkable on admission.

In particular, it would be helpful for clinicians if a laboratory test could predict neurologic complications. Recently, serum hyperammonemia has been suggested to indicate neurologic complications in glufosinate ammonium poisoning. However, existing reports regarding the serum ammonia level as a probable predictor of neurologic complications are limited to case reports or retrospective studies.^1,3,12
–14 We also reported that the initial serum ammonia level, which is performed at the emergency department (ED), may predict neurologic complications.¹²

We prospectively investigated serial serum ammonia level and occurrence of neurologic complications in glufosinate ammonium poisoning and attempted to determine a trend of serum ammonia levels according to the presence and recovery of neurologic complications.

Methods

Patients

This prospective observational study collected data from consecutive patients diagnosed with acute glufosinate ammonium poisoning between September 2014 and June 2016. The ED was located in a single, urban, tertiary-care hospital with more than 43,000 annual visits that is staffed 24 h a day by board-certified emergency physicians. This study was approved by the Institutional Review Board of Yonsei University Wonju College of Medicine (approval number: YWMR-14-7-059). Each participant received information regarding the study aims, and they all provided written informed consent.

Acute glufosinate ammonium poisoning was confirmed by patient or guardian statements, and a physician verified the agent and transcribed the bottle label into the patient records. All patients with hyperammonemia upon ED arrival received a lactulose enema to lower the ammonia level, as high levels have been suggested to cause neurologic complications.¹² All glufosinate ammonium–poisoned patients were admitted to the intensive care unit (ICU) for close observation for more than 1 day.

Patients were excluded for the following reasons: (1) poisoning with any additional material except for alcohol; (2) liver diseases, chronic renal disease, or cardiac arrest before ED arrival, chemotherapy, current urinary tract infection, gastrointestinal hemorrhage, or multiple myeloma, which can cause hyperammonemia; (3) a history of seizure; (4) presentation more than 12 h following ingestion; and (5) refusal to participate.

Study variables and definitions

The following clinical parameters were assessed: age, sex, ingested amount, intentionality of poisoning, co-ingestion of alcohol, time elapsed from ingestion to ED arrival, use of gastric irrigation or charcoal, medical history, initial vital signs, initial symptoms, and neurologic and nonneurologic complications upon admission, such as mental changes (Glasgow Coma Scale, GCS < 13), seizures, amnesia, intubation and mechanical ventilation, respiratory failure, shock (systolic blood pressure <90 mmHg), pneumonia, cardiac arrest during hospitalization, and inhospital mortality. We defined the amount of ingested glufosinate ammonium as follows: “a little” or “a spoonful” as 5 mL, “a mouthful” as 25 mL, “a small cup” as 100 mL, and “a bottle” as 300 mL.¹⁵ Respiratory failure was defined as hypoxia (partial pressure of arterial oxygen (PaO₂) < 70 mmHg) or hypercapnia (partial pressure of arterial carbon dioxide (PaCO₂) > 60 mmHg). Intubation and mechanical ventilator care were initiated if the patient required airway protection or respiratory failure treatment.

Laboratory parameters included serum ammonia level, arterial blood gas analysis, lactate, alanine transaminase (ALT), and creatinine (Cr). The serum ammonia level was obtained using a Dimension Vista® System (Siemens, Munich, Germany). Venous or arterial blood was collected in a tube containing lithium heparin to measure the ammonia concentrations. The tube was completely filled, tightly capped, stored on ice, and centrifuged without delay. The samples were analyzed within 30 min of centrifugation. The Dimension Vista Ammonia method is an enzymatic method that uses glutamate dehydrogenase and a stabilized nicotinamide adenine dinucleotide phosphate oxidase analog. Ammonia reacts with α-ketoglutarate and reduced cofactor to form l-glutamate and the cofactor. The reaction is catalyzed by glutamate dehydrogenase. The decrease in absorbance due to the oxidation of the reduced cofactor is monitored at 340/700 nm and is proportional to the ammonia concentration. The serum ammonia level was serially measured once more within 24 h after ED arrival (admission day 0), on admission days 1 and 2, and if the serum ammonia level was elevated (>54 μg/dL), then the serum ammonia level was followed daily until it is normalized. The peak ammonia level was defined as the highest serum ammonia level measured when neurologic complications occurred.

The patients were divided into two groups: the neurologic complication group (patients with mental changes, seizures, and amnesia during their hospital course) and the nonneurologic complication group (patients without these complications). We also evaluated patients poisoned with 25 other insecticides or herbicides that do not produce hyperammonemia to compare their serum ammonia level with glufosinate ammonium–poisoned patients; these patients were the control group.

Study end point

The primary outcome was to investigate the predictors of neurologic complications in acute glufosinate ammonium poisoning. The secondary outcome was evaluating the change of serum ammonia level as a predictor of patient’s presence and recovery of neurologic complication.

Statistical analysis

Data are expressed according to the properties of the variable. Continuous variables are presented as the mean and standard deviation or the median and range. Categorical variables are shown as a frequency and percentage. To compare the three groups, we performed a χ ² test (Fisher’s exact test), analysis of variance, or Kruskal–Wallis test as appropriate. We analyzed multiple comparisons using Bonferroni correction, Sheffé’s method, and/or Dunn’s procedure. If patients had neurologic complications, we conducted a paired t-test to compare their serum ammonia levels before and after recovery. Logistic regression analysis identified factors that predict neurologic complications, and the results were expressed as odds ratio (OR) with 95% confidence interval (CI). The area under the receiver operating characteristic (ROC) curve was used to evaluate the ability of serum ammonia for classifying neurologic complications. We suggested an optimal cutoff of serum ammonia using Youden’s Index. A p value less than 0.05 was statistically significant, and all statistical analyses were conducted using SAS version 9.4 (SAS Inc., Cary, North Carolina, USA).

Results

Patient characteristics

Between September 2014 and June 2016, 74,000 patients visited our hospital’s ED; 29 consecutive patients with acute glufosinate ammonium poisoning were identified, and 25 were finally included. The exclusion criteria were poisoning with zolpidem (one patient), liver diseases or renal disease that can cause hyperammonemia (two patients), and refusal to participate in this study (one patient).

All patients had ingested an herbicide containing 18.0% glufosinate; 56.0% were men, and the mean age was 55.3 years (range: 27–82 years). The poisoning was intentional in 96.0% of cases, and patients arrived at the ED a median of 2.0 h after ingestion. All patients presented to our hospital within 6 h of ingestion. Hypertension (28.0%) was the most common past medical condition. At their initial presentation, patients complained of nausea (63.0%), vomiting (31.8%), and dyspnea (31.8%). All patients received gastric irrigation or gastric lavage and activated charcoal.

We also analyzed the control group which contained 25 patients with poisoning from other insecticides or herbicides, including pyrethroid (nine patients, 36%), organophosphate (six patients, 24%), carbamate (five patients, 20%), glyphosate (three patients, 12%), organochlorine (one patient, 4%), and sethoxydim (one patient, 4%). Of these 25 patients, 48.0% were men. The mean age was 56.4 years (range: 32–80 years). The poisoning was intentional in 88.0% of cases, and the median duration between ingestion and ED arrival was 3.0 h (Table 1).

Table 1.

Baseline and clinical characteristics of 25 patients poisoned with glufosinate ammonium herbicide and 25 patients defined as the control group.

Variables	Control group (n = 25)	Nonneurologic Cx group (n = 7; 28.0%)	Neurologic Cx group (n = 18; 72.0%)	p Value
Age	56.4 ± 13.4^a	49.4 ± 16.2^a	57.6 ± 15.2^a	0.442
Male	12 (48.0%)	3 (42.9%)	11 (61.1%)	0.678
Ingested amounts (cc)	150 (100–200)^b	50 (50–200)^b,c	200 (150–300)^b,c	0.018
Intentionality	22 (88.0%)	6 (85.7%)	18 (100%)	0.252
Co-ingested alcohol	10 (40.0%)	3 (42.9%)	8 (44.4%)	1.000
ED arrival time (h)	3.0 (1.0-3.5)^b	3.0 (2.0–4.0)^b	2.0 (1.0–5.3)^b	0.868
Past history
DM	4 (16.0%)	1 (14.3%)	1 (5.6%)	0.497
HTN	6 (24.0%)	2 (28.6%)	5 (27.8%)	1.000
Hyperlipidemia	0 (0%)	1 (14.3%)	0 (0%)	0.140
Lung disease	3 (12.0%)	0 (0%)	1 (5.6%)	0.801
Initial vital signs
SBP (mmHg)	128 ± 34^a	135 ± 28^a	132 ± 22^a	0.853
PR (beats/min)	86 ± 21^a	85 ± 13^a	96 ± 25^a	0.320
RR (beats/min)	20 ± 2^a	19 ± 1^a	19 ± 2^a	0.284
BT (°C)	36.2 ± 0.8^a	36.3 ± 0.4^a	36.4 ± 0.9^a	0.903
Symptoms
Nausea	14/22 (63.6%)	4/7 (57.1%)	10/15 (66.7%)	1.000
Vomiting	9/22 (40.9%)	1/7 (14.3%)	6/15 (40.0%)	0.492
Abdominal pain	7/22 (31.8%)	0/7 (0%)	5/15 (33.3%)	0.247
Headache	1/22 (4.5%)	0/7 (0%)	2/15 (13.3%)	0.738
Dizziness	6/22 (27.3%)	1/7 (14.3%)	5/15 (33.3%)	0.665
Dyspnea	5/22 (22.7%)	1/7 (14.3%)	6/15 (40.0%)	0.427
Laboratory findings
pH	7.30 ± 0.20^a	7.38 ± 0.11^a	7.33 ± 0.10^a	0.540
PaO₂ (mmHg)	99.4 ± 26.6^a	110.6 ± 20.1^a	110.7 ± 27.5^a	0.327
PaCO₂ (mmHg)	36.1 ± 12.4^a	33.4 ± 7.1^a	30.7 ± 4.3^a	0.199
Bicarbonate (mmol/L)	17.5 ± 5.5^a	20.0 ± 4.9^a	17.0 ± 4.6^a	0.415
Lactate (mmol/L)	4.88 ± 4.32^a	2.68 ± 2.06^a	3.26 ± 2.36^a	0.191
ALT (U/L)	21 (19–30)^b	20 (16–24)^b	20 (18–27)^b	0.641
Creatinine (mg/dL)	0.88 ± 0.32^a	0.72 ± 0.11^a	0.85 ± 0.30^a	0.467
Peak ammonia (µg/dL)	26.36 ± 9.42^a,d	56.29 ± 21.24^a ^,c	118.33 ± 52.91^a ^,c,d	<0.001

Cx: complications; ED: emergency department; DM: diabetes mellitus; HTN: hypertension; SBP: systolic blood pressure; PR: pulse rate; RR: respiratory rate; BT: body temperature; PaO₂: partial pressure of arterial oxygen; PaCO₂: partial pressure of arterial carbon dioxide; ALT: alanine transaminase.

^aMean ± standard deviation.

^bMedian (interquartile range).

^cNonneurologic Cx group versus neurologic Cx group (ingested amounts: p value = 0.009, serum peak ammonia: p value = 0.001).

^dControl group versus neurologic Cx group (serum peak ammonia: p value < 0.001).

Incidence and patterns of complications in acute glufosinate ammonium poisoning

Neurologic complications during hospitalization after glufosinate ammonium poisoning were mental change (18 patients, 72.0%), seizure (7 patients, 28.0%), and amnesia (8 patients, 34.8%). All neurologic complication group patients experienced mental changes. All patients reported neurologic complications within admission day 1 (within 48 h postingestion). Of the 18 patients with mental changes, 10 patients (58.8%) reported the changes (GCS < 13) on admission day 0 (within 24 h postingestion). Of these 10 patients, seven patients arrived at the ED with an alert mental status and reported the mental change while in the ED; the other three patients arrived at the ED with a decreased mental status. The remaining eight patients (44.4%) reported a mental change on admission day 1 and experienced no neurologic complications on admission day 0. The median recovery time was 2.5 days in 17 of 18 patients with mental changes; and one patient did not recover a normal mental status due to hypoxic brain injury following cardiac arrest during admission before recovery from a decreased mental status. Seven patients experienced seizures: two (28.6%) on admission day 0 (within 24 h postingestion) and five (71.4%) on admission day 1 (within 48 h postingestion).

Nonneurologic complications included intubation and mechanical ventilation (12 patients, 48.0%), shock (four patients, 16.0%), pneumonia (seven patients, 28.0%), and cardiac arrest (two patients, 8.0%). One patient died from pneumonia during hospitalization (Table 2).

Table 2.

A comparison of nonneurologic complications according to the presence of neurologic complications.

Variables	Total (n = 25)	Nonneurologic Cx group (n = 7; 28.0%)	Neurologic Cx group (n = 18; 72.0%)	p Value
Intubation and mechanical ventilator	12 (48.0%)	0 (0%)	12 (66.7%)	0.005
Due to mental changes	7 (58.4%)	0 (0%)	7 (58.4%)
Due to respiratory failure	5 (41.6%)	0 (0%)	5 (41.6%)
Shock	4 (16.0%)	0 (0%)	4 (22.2%)	0.294
Use of inotropic	4 (16.0%)	0 (0%)	4 (22.2%)	0.294
Pneumonia	7 (28.0%)	0 (0%)	7 (38.9%)	0.133
Cardiac arrest	2 (8.0%)	0 (0%)	2 (11.1%)	1.000
ICU admission days	4.0 (2.0–8.0)^a	2.0 (1.0–2.0)^a	6.5 (3.8–11.3)^a	0.001
Inhospital mortality	1 (4.0%)	0 (0%)	1 (5.6%)	1.000

Cx: complications; ICU: intensive care unit.

^aMedian (interquartile range)

Comparisons between the control group, nonneurologic complication group, and neurologic complication group

A comparison of patient characteristics is shown in Table 1. The neurologic complication group comprised 18 patients (72.0%) with glufosinate ammonium poisoning. Patients in each group differed in terms of ingested amount (p = 0.018) and peak ammonia level (p < 0.001). Statistical differences were observed for the ingested amounts between the nonneurologic complication group and the neurologic complication group (p = 0.009) in multiple comparison. The peak ammonia level was statistically higher in the neurologic complication group than in the control group (p < 0.001) and nonneurologic complication groups (p = 0.001) in multiple comparison (118.33 μg/dL vs. 26.36 μg/dL vs. 56.29 μg/dL; Table 1 and Figure 1).

Figure 1.

The mean peak ammonia level in each groups. Cx: complications.

A subgroup analysis of serum ammonia level was based on the presence of neurologic complications and the day they developed and revealed that patients with neurologic complications on admission day 0 (within 24 h postingestion) had a statistically higher serum ammonia level than the nonneurologic complication group. In patients with neurologic complications on admission day 1 (within 48 h postingestion), an increase in the serum ammonia level was seen the next day, although there was no statistical difference among the three groups (Table 3 and Figure 2).

Table 3.

Serial patterns of serum ammonia in each group.

	Nonneurologic Cx group	Neurologic Cx group in the admission day 0	Neurologic Cx group on admission day 1	p Value
Ammonia 0	56.29 ± 21.24^a,b	117.82 ± 53.12^a,b	92.57 ± 50.84^a	0.037
Ammonia 1	71.14 ± 16.77^a	92.27 ± 45.95^a	117.00 ± 56.93^a	0.169

Cx: complications; ammonia 0: serum ammonia level checked on admission day 0; ammonia 1: serum ammonia level checked on admission day 1.

^aMean ± standard deviation.

^bNonneurologic Cx group versus neurologic Cx group on admission day 0 (ammonia 0: p = 0.037).

Figure 2.

Serial pattern of serum ammonia in each groups. Cx: complications; ammonia 0: serum ammonia level, which was performed on admission day 0 (within 24 h postingestion); ammonia 1: serum ammonia level, which was performed on admission day 1 (within 48 h postingestion).

ALT, pH, bicarbonate, and Cr levels did not differ during the first 48 h after ingestion between the three groups. There were also no statistically significant differences between the control group and the glufosinate ammonium poisoning group regarding their baseline characteristics (Table 1).

The neurologic complication group was more likely to receive intubation and mechanical ventilator care than the nonneurologic complication group (p = 0.005). The median ICU admission length was statistically longer in the neurologic complication group than in the nonneurologic complication group (6.5 days and 2.0 days, respectively, p = 0.001; Table 2).

Predictors of neurologic complications and change of serum ammonia after recovery of neurologic complications

Multiple logistic regression analyses to determine factors related to the development of neurologic complications identified peak ammonia level (OR: 1.075, 95% CI: 1.004–1.152, p = 0.038) as statistically significant. The optimal point of peak ammonia level was 90 μg/dL (sensitivity: 72%, specificity: 100%, and area under the curve: 0.881) according to ROC curves and the Youden Index (Table 4).

Table 4.

Predictors of neurologic complications as determined by multivariate logistic regression analysis.

	Univariate analysis		Multivariate analysis
Variables	OR (95% CI)	p Value	OR (95% CI)	p Value
Ingested amounts	1.015 (1.000–1.030)	0.046	1.019 (1.000–1.038)	0.051
Peak ammonia level	1.052 (1.006–1.100)	0.026	1.075 (1.004–1.152)	0.038

OR: odds ratio; CI: confidence interval.

In patients with mental changes, the mean peak ammonia levels were statistically different from the serum ammonia level, which was assessed when the mental changes disappeared (118.33μg vs. 70.65μg/dL, p = 0.002). In the neurologic complication group, the serum peak ammonia level in seizure patients was higher than that in patients without seizure, although there was no statistically significant difference (135.71 μg/dL vs. 107.27 μg/dL, p = 0.279; Table 5).

Table 5.

Change in serum ammonia level between altered mental status and recovered mental status in the neurologic complication group.

Recovery status	Serum ammonia level	p Value
Altered mental status	118.33 ± 52.91^a	0.002
Recovered mental status	70.65 ± 26.31^a

^aMean ± standard deviation.

Discussion

Predictors of neurologic complications and change of serum ammonia after recovery of neurologic complications

This study prospectively confirmed that the peak ammonia level was an only predictor of neurologic complications in acute glufosinate ammonium poisoning. The mean peak ammonia level of patients with mental changes was statistically different from the serum ammonia level of when the mental change is resolved. Therefore, treating the hyperammonemia in acute glufosinate ammonium poisoning is important to recover the patient’s neurological complications.

Because glufosinate is an inhibitor of synthesis of glutamine from glutamate and ammonia in plants, the intracellular accumulation of ammonia can cause tissue necrosis and death.^1
–3 Although few studies are available regarding the effects of glufosinate on mammals, there may be some similarity between mammalian and plant GS. In those studies, increased hepatic ammonia levels were found at more than a sublethal dose of glufosinate exposure; the increased ammonia level effect can be partially attributed to mammalian GS inhibition.^9,16

The arterial ammonia level is not well correlated with the brain ammonia level because the brain does not significantly take ammonia up from the arterial blood under normal physiological conditions. It has been debated whether ammonia enters the brain through passive diffusion and/or active transport by ion transporters. However, if the arterial ammonia level is elevated, increased uptake of ammonia by the brain can occur.^17,18 In addition, the formulated anionic surfactant contained in glufosinate herbicide may increase the uptake of ammonia into the brain by increasing the permeability of the blood–brain barrier.¹⁹ Therefore, in acute glufosinate ammonium–poisoned patients, increases in the serum ammonia level may raise brain ammonia levels.

Elevated ammonia in the brain can induce the activation of N-methyl-d-aspartate, which increases intracellular calcium ions and nitric oxide. Therefore, a rise in the brain ammonia level following glufosinate ammonium poisoning may increase the intracellular calcium ion and nitric oxide levels. This effect can inhibit GS in nearby astrocytes and also increase the consumption and decrease the synthesis of adenosine triphosphate; cellular death may eventually result.²⁰ Therefore, because acute glufosinate ammonium poisoning may cause serum hyperammonemia and the increased ammonia level may produce neurologic complications, the peak ammonia level can be an only predictor of neurologic complications in acute glufosinate-poisoned patients and the serum ammonia levels can be decreased when the mental change resolved. According to our results, serial serum ammonia level checks are needed.

Incidence of complications and comparisons between the nonneurologic complication group and the neurologic complication group

In this study, 72.0% of the patients were placed in the neurologic complication group. Some differences in the incidence of neurologic complications in previous studies exist^3,5,12,13 that may have occurred due to the definition of complication group and the severity of poisoned patients. However, similarities in the results of recent human studies (including our prospective study) indicate that acute glufosinate ammonium poisoning causes serious complications much more often than previously reported.^3,5,12,13 Accordingly, we should remember that glufosinate ammonium is not safe for human ingestion. This study also reconfirmed that neurologic complications frequently appeared after an asymptomatic interval of several hours. Therefore, we suggest that glufosinate ammonium–poisoned patients with no symptoms upon ED arrival receive close observation to detect serious complications, including mental changes, seizures, and the need for intubation and mechanical ventilation.

In acute glufosinate poisoning, various complications are associated with the ingested amount. In our previous study, as well as those of Mao et al. and Inoue et al., the ingested amounts were not statistically different between the noncomplicated group and the complicated group.^3,12,13 However, in Moon et al.’s study, the ingested amount was significantly higher in the complicated group than in the noncomplicated group.⁵ In the present study, the ingested amount was statistically higher in the neurologic complication group than in the nonneurologic complication group. This difference may be because it is difficult to accurately measure ingested amounts, especially in patients with decreased mental status. However, unlike the previous retrospective study, we prospectively investigated the ingested amounts, so the confidence of our results is higher.

Although hyperammonemia can be a secondary phenomenon of acidosis, shock, and renal and hepatic dysfunction, which may be toxic manifestations of glufosinate ammonium poisoning,⁵ the serum ALT, Cr, pH, and arterial bicarbonate levels during the first 48 h after ingestion did not differ between the two groups.

In this study, intubation and mechanical ventilation were statistically higher in the neurologic complication group than in the nonneurologic complication group, and there were no nonneurologic complications, including intubation and mechanical ventilator care, in the nonneurologic complication group; only the neurologic complication group demonstrated nonneurologic complications. Therefore, it is important to anticipate neurologic complications, since they may also predict various nonneurologic complications. Intubation and mechanical ventilation may be required in glufosinate ammonium poisoning, such as with neurologic complications like mental changes and seizures, to protect the airway. In addition, respiratory suppression requiring mechanical ventilation may be caused by the glufosinate itself. Reports about respiratory suppression by glufosinate showed that the prognosis of patients significantly depends on the management of respiratory arrest.⁶ In this study, 12 patients received intubation and mechanical ventilator care: five intubations for respiratory failure without mental change and seven intubations due to decreased mental changes and uncontrollable seizures. Because mechanical ventilator care and decreased mental status were higher in the neurologic complication group, ICU admission days were statistically longer in the neurologic complication group.

Study limitations

This study had some limitations. First, the number of patients was small due to it being a single-center study. Second, we could not exclude the effects of the contained surfactant. However, the ingested glufosinate concentration was 18% in all patients. Third, patient initial mental status can be affected by the co-ingestion of alcohol and glufosinate herbicide. Although the lack of evaluation of the presence of alcohol co-ingestion using the serum ethanol level in all included patients was a limitation of our study, there were no differences in the incidence of alcohol co-ingestion between the nonneurologic complication group and the neurologic complication group. Further studies are required to clarify these details.

Conclusions

In acute glufosinate poisoning, serial serum ammonia level measurements are needed and a serum peak ammonia level greater than 90 μg/dL is a predictor of neurologic complications. Also, it is important to treat the hyperammonemia in acute glufosinate ammonium poisoning.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

Watanabe

Sano

. Neurological effects of glufosinate poisoning with a brief review. Hum Exp Toxicol 1998; 17: 35–39.

Hoerlein

. Glufosinate (phosphinothricin), a natural amino acid with unexpected herbicidal properties. In: Whitacre

(ed) Reviews of Environmental Contamination and Toxicology. Springer, 1994, pp. 73–145.

Mao

Hung

. Acute human glufosinate-containing herbicide poisoning. Clin Toxicol (Phila) 2012; 50: 396–402.

Lin

Kuo

. Two cases of acute Basta poisoning with discordant clinical courses at similar lethal doses. Acta Nephrologica 2008; 22: 124–127.

Moon

Chun

. Serial ammonia measurement in patients poisoned with glufosinate ammonium herbicide. Hum Exp Toxicol 2016; 35: 554–561.

Hirose

Kobayashi

Koyama

. A toxicokinetic analysis in a patient with acute glufosinate poisoning. Hum Exp Toxicol 1999; 18: 305–308.

Koyama

Andou

Saruki

. Delayed and severe toxicities of a herbicide containing glufosinate and a surfactant. Vet Hum Toxicol 1994; 36: 17–18.

Ebert

Leist

Mayer

. Summary of safety evaluation toxicity studies of glufosinate ammonium. Food Chem Toxicol 1990; 28: 339–349.

Hack

Ebert

Ehling

. Glufosinate ammonium—some aspects of its mode of action in mammals. Food Chem Toxicol 1994; 32: 461–470.

10.

Kyong

Choi

. “Hyperammonemia following glufosinate-containing herbicide poisoning: a potential marker of severe neurotoxicity” by Yan-Chido Mao et al., Clin Toxicol (Phila) 2011; 49: 48–52. Clin Toxicol (Phila) 2011; 49: 510–512; author reply 513.

11.

Tominaga

Izumi

Suzukawa

. Takotsubo cardiomyopathy as a delayed complication with a herbicide containing glufosinate ammonium in a suicide attempt: a case report. Case Rep Med 2012; 2012: 630468.

12.

Lee

Youk

Kim

. Initial serum ammonia as a predictor of neurologic complications in patients with acute glufosinate poisoning. Yonsei Med J 2016; 57: 254–259.

13.

Inoue

Onodera

Fujita

. Factors associated with severe effects following acute glufosinate poisoning. Clin Toxicol (Phila) 2013; 51: 846–849.

14.

Mao

Wang

Hung

. Hyperammonemia following glufosinate-containing herbicide poisoning: a potential marker of severe neurotoxicity. Clin Toxicol (Phila) 2011; 49: 48–52.

15.

Yang

Lin

Hall

. Acute ingestion poisoning with insecticide formulations containing the pyrethroid permethrin, xylene, and surfactant: a review of 48 cases. J Toxicol Clin Toxicol 2002; 40: 107–113.

16.

Krajewski

Collins

Holmberg-Schiavone

. Crystal structures of mammalian glutamine synthetases illustrate substrate-induced conformational changes and provide opportunities for drug and herbicide design. J Mol Biol 2008; 375: 217–228.

17.

Sørensen

Keiding

. New findings on cerebral ammonia uptake in HE using functional 13N-ammonia PET. Metab Brain Dis 2007; 22: 277–284.

18.

Sørensen

. Update on cerebral uptake of blood ammonia. Metab Brain Dis 2013; 28: 155–159.

19.

Saija

Princi

Trombetta

. Changes in the permeability of the blood-brain barrier following sodium dodecyl sulphate administration in the rat. Exp Brain Res 1997; 115: 546–551.

20.

Rodrigo

Cauli

Boix

. Role of NMDA receptors in acute liver failure and ammonia toxicity: therapeutical implications. Neurochem Int 2009; 55: 113–118.